Oasmia
  • About Oasmia
    • About Oasmia
    • Vision & goals
    • Our Technology
    • Production
    • History
    • Research & Development
    • Board of Directors
    • Management
    • Department Directors
  • Investor Relations
    • Investor Relations EU
      • Investor Relations EU
      • Press Releases
      • The share
        • The share
        • Shareholders
      • Current reports
      • Calendar
      • Corporate Governance
        • Corporate Governance
        • Board of Directors
          • Board of Directors
          • Chairman of the Board
          • Work plan for the Board of Directors
          • Audit committee
          • Remuneration committee
        • Management
        • Department Directors
        • Nomination committee
        • General Meetings
        • Warrant program
        • Articles of Association
        • Code of Business Conduct and Ethics
        • Auditor
        • Corporate Governance reports
      • Subscribe
    • Investor Relations US
  • Market
    • Market Human Health
    • Market Animal Health
  • Media
    • Media Contact
    • Press Releases
  • Contact
  • Career
  • sv
Navigation

Investor Relations

  • Overview
  • News / Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Profile
    • Presentations
    • Management Team
    • Contacts
    • FAQ
  • Current Reports
  • Stock Data
    • Overview
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Investor Tools
    • Email Alerts
    • Tear Sheet
    • Contacts
    • RSS News Feed
  • Home /
  • Investors /
  • All SEC Filings

All SEC Filings



Date Form Description PDF XBRL Pages
02/05/19 6-K Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
Documents
EX-99.1
6
02/01/19 6-K Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
Documents
EX-99.1
4
01/22/19 6-K Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
Documents
EX-99.1
5
01/22/19 6-K Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
Documents
EX-99.1
5
01/15/19 6-K Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
Documents
EX-99.1
5
12/19/18 6-K Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
Documents
EX-99.1
6
12/17/18 6-K Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
Documents
EX-99.1
8
12/14/18 6-K Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
Documents
EX-99.1
6
12/03/18 6-K Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
Documents
EX-99.1
4
11/30/18 6-K Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
Documents
EX-99.1
EX-99.2
30
RSS
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
Facebook Facebook Twitter Twitter LinkedIn LinkedIn Google+ Google+ Email Email
Oasmia Pharmaceutical AB
Vallongatan 1
SE 752 28 Uppsala, Sweden
Tel +46 18 50 54 40
Fax +46 18 51 08 73
info@oasmia.com
Org no 556332-6676
Twitter Facebook
Copyright © 2010-2019 Oasmia